Cargando…

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease

BACKGROUND: The only conclusive way to diagnose Alzheimer’s is to carry out brain autopsy of the patient’s brain tissue and ascertain whether the subject had Alzheimer’s or any other form of dementia. However, due to the non-feasibility of such methods, to diagnose and conclude the conditions, medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Sahil, Barve, Kalyani H., Kumar, Maushmi S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709159/
https://www.ncbi.nlm.nih.gov/pubmed/32484110
http://dx.doi.org/10.2174/1570159X18666200528142429
_version_ 1783617693668081664
author Khan, Sahil
Barve, Kalyani H.
Kumar, Maushmi S.
author_facet Khan, Sahil
Barve, Kalyani H.
Kumar, Maushmi S.
author_sort Khan, Sahil
collection PubMed
description BACKGROUND: The only conclusive way to diagnose Alzheimer’s is to carry out brain autopsy of the patient’s brain tissue and ascertain whether the subject had Alzheimer’s or any other form of dementia. However, due to the non-feasibility of such methods, to diagnose and conclude the conditions, medical practitioners use tests that examine a patient’s mental ability. OBJECTIVE: Accurate diagnosis at an early stage is the need of the hour for initiation of therapy. The cause for most Alzheimer’s cases still remains unknown except where genetic distinctions have been observed. Thus, a standard drug regimen ensues in every Alzheimer’s patient, irrespective of the cause, which may not always be beneficial in halting or reversing the disease progression. To provide a better life to such patients by suppressing existing symptoms, early diagnosis, curative therapy, site-specific delivery of drugs, and application of hyphenated methods like artificial intelligence need to be brought into the main field of Alzheimer’s therapeutics. METHODS: In this review, we have compiled existing hypotheses to explain the cause of the disease, and highlighted gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics and quantum dots as advancements in the existing strategies to manage Alzheimer’s. CONCLUSION: Biomarkers, brain-imaging, and theranostics, along with artificial intelligence, are understood to be the future of the management of Alzheimer’s.
format Online
Article
Text
id pubmed-7709159
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-77091592021-05-01 Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease Khan, Sahil Barve, Kalyani H. Kumar, Maushmi S. Curr Neuropharmacol Article BACKGROUND: The only conclusive way to diagnose Alzheimer’s is to carry out brain autopsy of the patient’s brain tissue and ascertain whether the subject had Alzheimer’s or any other form of dementia. However, due to the non-feasibility of such methods, to diagnose and conclude the conditions, medical practitioners use tests that examine a patient’s mental ability. OBJECTIVE: Accurate diagnosis at an early stage is the need of the hour for initiation of therapy. The cause for most Alzheimer’s cases still remains unknown except where genetic distinctions have been observed. Thus, a standard drug regimen ensues in every Alzheimer’s patient, irrespective of the cause, which may not always be beneficial in halting or reversing the disease progression. To provide a better life to such patients by suppressing existing symptoms, early diagnosis, curative therapy, site-specific delivery of drugs, and application of hyphenated methods like artificial intelligence need to be brought into the main field of Alzheimer’s therapeutics. METHODS: In this review, we have compiled existing hypotheses to explain the cause of the disease, and highlighted gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics and quantum dots as advancements in the existing strategies to manage Alzheimer’s. CONCLUSION: Biomarkers, brain-imaging, and theranostics, along with artificial intelligence, are understood to be the future of the management of Alzheimer’s. Bentham Science Publishers 2020-11 2020-11 /pmc/articles/PMC7709159/ /pubmed/32484110 http://dx.doi.org/10.2174/1570159X18666200528142429 Text en © 2020 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Khan, Sahil
Barve, Kalyani H.
Kumar, Maushmi S.
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
title Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
title_full Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
title_fullStr Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
title_full_unstemmed Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
title_short Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
title_sort recent advancements in pathogenesis, diagnostics and treatment of alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709159/
https://www.ncbi.nlm.nih.gov/pubmed/32484110
http://dx.doi.org/10.2174/1570159X18666200528142429
work_keys_str_mv AT khansahil recentadvancementsinpathogenesisdiagnosticsandtreatmentofalzheimersdisease
AT barvekalyanih recentadvancementsinpathogenesisdiagnosticsandtreatmentofalzheimersdisease
AT kumarmaushmis recentadvancementsinpathogenesisdiagnosticsandtreatmentofalzheimersdisease